» Articles » PMID: 30523401

Cytotoxic Natural Killer Subpopulations As a Prognostic Factor of Malignant Pleural Effusion

Overview
Journal Lung
Specialty Pulmonary Medicine
Date 2018 Dec 8
PMID 30523401
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Malignant pleural effusion (MPE) is a sign of advanced disease of poor prognosis. As natural killer (NK) cells are involved in the first line of tumour defence, we aimed to validate a new diagnostic and prognostic indicator for MPE based on NK subpopulations of pleural fluid (PF) and peripheral blood (PB).

Methods: NK subpopulations were determined in PF and PB in 71 patients with malignant, paramalignant or benign pleural effusion. The receiver operating characteristic (ROC) curves, Kaplan-Meier, multivariable Cox model and decision trees created with the CHAID (Chi-square automatic interaction detector) methodology were employed.

Results: We demonstrated that the PF/PB ratios of the CD56 bright CD16- and CD56 dim CD16- NK subpopulations were higher (p = 0.013 and p = 0.003, respectively) in MPEs and paramalignant pleural effusions (PPEs) than in benign ones, with an AUC of 0.757 and 0.741, respectively. The PF/PB ratio of CD16+ NK and CD57+ NK obtained a higher hazard ratio (HR) in the crude Cox's regression analysis. In the adjusted Cox's regression analysis, the PF/PB ratio of CD16+ NK gave the highest HR (HR 6.1 [1.76-21.1]) (p = 0.004). In the decision tree created for the MPE prognosis, we observed that the main predictor variable among the studied clinical, radiological, and analytical variables was lung mass, and that 92.9% of the patients who survived had a PF/PB ratio of the CD56 dim CD16+ NK subpopulation ≤ 0.43.

Conclusions: Our data suggest that both the PF/PB ratios of cytotoxic subpopulations CD57+ NK and CD16+ NK are useful as a prognostic factor of MPE. Other subpopulations (CD56 bright CD16- and CD56 dim CD16- NK) could help to diagnose MPE.

Citing Articles

Impact of thoracic tumor radiotherapy on survival in non-small-cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study.

Li Q, Hu C, Su S, Ma Z, Geng Y, Hu Y Cancer Med. 2023; 12(14):14949-14959.

PMID: 37288833 PMC: 10417183. DOI: 10.1002/cam4.6130.


Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion.

Mehraban Z, Pourdowlat G, Mortaz E, Atefeh A, Ghaforian A, MalAmir M J Family Med Prim Care. 2023; 11(11):6843-6847.

PMID: 36993098 PMC: 10041266. DOI: 10.4103/jfmpc.jfmpc_2296_21.

References
1.
Scherpereel A, Grigoriu B, Noppen M, Gey T, Chahine B, Baldacci S . Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid. BMC Cancer. 2013; 13:324. PMC: 3718618. DOI: 10.1186/1471-2407-13-324. View

2.
. Management of malignant pleural effusions. Am J Respir Crit Care Med. 2000; 162(5):1987-2001. DOI: 10.1164/ajrccm.162.5.ats8-00. View

3.
Green L, Griffin J . Increased natural killer cells in fluids. A new, sensitive means of detecting carcinoma. Acta Cytol. 1996; 40(6):1240-5. DOI: 10.1159/000333987. View

4.
Jezewska E, Sikora J, Zeromski J . Evaluation of immunophenotype of lymphoid cells isolated from malignant pleural effusions. Arch Immunol Ther Exp (Warsz). 1993; 41(1):51-6. View

5.
Yu G, Hida C, Salhany K, Baloch Z, Gupta P . Immunohistochemical detection of cytotoxic lymphocytes in malignant serous effusions. Diagn Cytopathol. 1999; 21(1):18-21. DOI: 10.1002/(sici)1097-0339(199907)21:1<18::aid-dc6>3.0.co;2-g. View